SCHEMBL363487

SCHEMBL363487

CC(C)CC(=O)OC(=O)/C=C/c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
ALDH1A1 P00352 2/20 0.50
AKR1B10 O60218 3/20 0.48
AKR1B1 P15121 3/20 0.48
TDP1 Q9NUW8 2/20 0.47
GLA P06280 1/20 0.47
KMT2A Q03164 4/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
MAPT P10636 2/20 0.46
HDAC3 O15379 1/20 0.46
TNKS O95271 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HCAR2 Q8TDS4 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
TNKS2 Q9H2K2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28433698 1.00 LMNA (0.50) LMNAALDH1A1AKR1B10AKR1B1TDP1
SCHEMBL30472929 0.84 LMNA (0.63) LMNATDP1KMT2AMAPTHDAC3
SCHEMBL28197285 0.84 ALDH1A1 (0.47) LMNAALDH1A1AKR1B10AKR1B1TDP1
SCHEMBL27732203 0.83 LMNA (0.56) LMNAALDH1A1AKR1B10AKR1B1TDP1
SCHEMBL27732204 0.83 LMNA (0.56) LMNAALDH1A1AKR1B10AKR1B1TDP1
SCHEMBL15569161 0.82 LMNA (0.51) LMNAALDH1A1AKR1B10AKR1B1TDP1
SCHEMBL11317021 0.82 LMNA (0.57) LMNAALDH1A1AKR1B10AKR1B1TDP1
SCHEMBL9116949 0.82 LMNA (0.57) LMNAALDH1A1AKR1B10AKR1B1TDP1
SCHEMBL29010570 0.79 LMNA (0.51) LMNAALDH1A1AKR1B10AKR1B1TDP1
SCHEMBL28160312 0.79 GLA (0.53) LMNAALDH1A1AKR1B10AKR1B1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111363415-A Slow-odor type high-strength nano composite colored lead core and preparation method thereof 烟台好前程文具有限公司 2020-07-03 CN claimed
WO-2010105922-A1 IMPROVEMENTS RELATING TO BENEFIT AGENT DELIVERY UNILEVER PLC (GB) 2010-09-23 WO claimed
EP-1567629-B1 LAUNDRY TREATMENT COMPOSITIONS AND COMPONENTS THEREFOR UNILEVER PLC (GB) 2007-03-07 EP claimed
CN-111363415-A Slow-odor type high-strength nano composite colored lead core and preparation method thereof 烟台好前程文具有限公司 2020-07-03 CN disclosed
CN-106604715-B Use of benefit delivery particles for off-flavour benefits 荷兰联合利华有限公司 2020-04-17 CN disclosed
CN-110461419-A It is provided with the cosmetic preparation of mesh CHANEL PARFUMS BEAUTE 2019-11-15 CN disclosed
EP-2911643-B1 IMPROVEMENTS RELATING TO ENCAPSULATED BENEFIT AGENTS UNILEVER PLC (GB) 2018-12-05 EP disclosed
US-10117815-B2 Improvements relating to encapsulated benefit agents CONOPCO, INC. (US) 2018-11-06 US disclosed
US-10034818-B2 Use of a benefit delivery particle for malodour benefit CONOPCO, INC. (US) 2018-07-31 US disclosed
EP-3148650-B1 BENEFIT DELIVERY PARTICLE FOR TREATING SUBSTRATES UNILEVER PLC (GB) 2018-07-04 EP disclosed
US-9993401-B2 Benefit delivery particle, process for preparing said particle, compositions comprising said particles and a method for treating substrates CONOPCO, INC. (US) 2018-06-12 US disclosed
US-20030068495-A1 Treatment for substrates UNILEVER HOME & PERSONAL CARE USA 2003-04-10 US disclosed
WO-2003020770-A1 POLYMERS AND THEIR USE UNILEVER PLC (GB) 2003-03-13 WO disclosed
WO-2003020819-A1 LAUNDRY TREATMENT COMPOSITIONS UNILEVER PLC (GB) 2003-03-13 WO disclosed
WO-2003014278-A1 TREATMENT FOR SUBSTRATES UNILEVER PLC (GB) 2003-02-20 WO disclosed
WO-2003010206-A1 POLYMERS AND THEIR SYNTHESIS UNILEVER PLC (GB) 2003-02-06 WO disclosed
WO-2003010268-A1 USE OF COMPOUNDS IN PRODUCTS FOR LAUNDRY APPLICATIONS UNILEVER PLC (GB) 2003-02-06 WO disclosed
WO-2003010267-A1 USE OF POLYMERS IN FABRICS CLEANING UNILEVER PLC (GB) 2003-02-06 WO disclosed
EP-1117755-A1 TREATMENT FOR SUBSTRATES UNILEVER PLC (GB) 2001-07-25 EP disclosed
WO-2000018861-A1 TREATMENT FOR SUBSTRATES UNILEVER PLC (GB) 2000-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10117815-B2 Improvements relating to encapsulated benefit agents CD44, HSPA2, HSPA1A LMNA 821/4885ALDH1A1 238/4885AKR1B10 1813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.